Variants in the metabolic genes NAT1, NAT2, GSTM1 or GSTT1, may cause differences in individual detoxifying capacity of possible carcinogens. We examined the cumulative effect of putative at risk genotypes on breast cancer risk and we examined the extent to which these polymorphisms modify the association between smoking and breast cancer. A case cohort study was conducted in the DOM cohort with 676 breast cancer cases and a random sample of 669 individuals. No effect of the NAT1, NAT2 or GSTM1 genotypes on breast cancer risk was observed. However, women with GSTT1 null genotype had a 30% increased breast cancer risk compared to women with GSTT1 present (RR = 1.30 (95% confidence interval (CI) 1.04-1.64)). Smoking did not influence breast cancer risk nor did genetic variations in NAT1, NAT2 or GSTM1 in combination with smoking. Compared to women who never smoked with GSTT1 present, women with GSTT1 null genotype and who formerly smoked showed an increased breast cancer risk (RR = 2.55 (95% CI 1.10-5.90)), but current smokers who smoked 20 cigarettes or more per day did not (RR = 1.06 (95% CI 0.51-2.18)). Increasing numbers of putative at risk genotypes increased breast cancer risk in a dose dependent manner (p for trend 0.01). The risk was more than doubled in women with all four risk genotypes, RR = 2.45 (95% CI 1.24-4.86), compared to women with zero putative at risk genotypes. In conclusion, the results of this study suggest that presence of three or more putative at risk genotypes increases breast cancer risk.
Introduction N-acetyltransferase 1 and 2 (NAT1, NAT2), glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) are phase II enzymes, involved in carcinogen metabolism. The genes coding for the NAT enzymes contain polymorphic sites, which cause variable enzymatic activity [1] .
GSTM1 or GSTT1 null genotype results in a complete lack of enzymatic activity [2] . Individual efficiency to metabolize carcinogens is determined by genetic factors. Polymorphisms in these genes have been associated with an increased risk of several cancers [1] .
Several risk factors for breast cancer have been studied, and they may be genetic or environmental or a combination. Among those, smoking is one of the most widely studied environmental risk factor for breast cancer. Results for smoking are inconclusive, but a pooling of 40 studies showed an increased risk for ever smoking of 1.10 (95% confidence interval (CI) 1.02-1.18) [3] . Another recent meta-analysis suggests no relation between smoking and breast cancer overall [4] . However, there may be women who are more susceptible for smoking than others because of their genetic composition. Groups of tobacco related carcinogens are converted into metabolites by cytochrome P450 related enzymes. Phase II enzymes are involved in subsequent detoxification of activated metabolites of carcinogens. Both NAT1 and NAT2 are involved in the activation and deactivation of aromatic and heterocyclic amines that can form DNA adducts [5] . Carcinogen-DNA adducts associated with tobacco smoke have been detected in human breast tissue and the mean adduct value was higher for breast cancer cases than for controls [6] . Several studies examined the relation between one genotype and breast cancer, but not all included smoking data or did combine different genotypes [7] [8] [9] .
The aim of the present study was to investigate both the combined effects of smoking and genetic polymorphisms in relevant metabolic genes (NAT1, NAT2, GSTM1 and GSTT1) and the cumulative effect of putative at risk genotypes on breast cancer risk.
Subjects and methods

Study subjects
A population-based screening program for early detection of breast cancer was started in 1974, in Utrecht, The Netherlands, the 'DOM' project (Diagnostisch Onderzoek Mammacarcinoom). The project was carried out in four cohorts. Between 1974 and 1979, all Women of the DOM 2 cohort did not provide a urine sample. The participation rate was 70% [10] .
In cooperation with all general practitioners in the region, a breast cancer incidence registry was set up, starting in 1974. From 1987 onwards, the regional cancer registry covered the identification of new cancers, as part of the Netherlands Cancer Registry. Follow-up from 1974 until January 1, 1996 revealed 942 incident breast cancer cases. For the present study 1000 controls were randomly selected from the DOM 1 (800), DOM 3 (160) and DOM 4 (40) cohorts based on the baseline numbers of each DOM cohort with a relatively oversampling of DOM 1 cohort because most cases were expected in this subcohort. During the follow-up 31.1% was censored due to moving out of the study area or death (DOM 1, 32.7%; DOM 3, 42.0%; DOM 4, 12.5%). The mean follow-up time for the random cohort sample was 15.8 years (standard deviation 5.20). The institutional review board for human studies of the University Medical Center Utrecht approved the study.
DNA isolation
DNA was isolated from urine by alcohol precipitation as described earlier [11] . Urine samples of the study population were thawed overnight at room temperature, mixed vigorously and 50 ml was used for DNA isolation. In brief, after centrifugation, DNA was isolated from the urine pellet by protein precipitation and DNA was precipitated by alcohol. DNA was finally resuspended in 40 ll (10 mM Tris, 1 mM EDTA, pH 7.6 (TE)).
Genotype NAT1 polymorphisms were detected by radioactive dot blot as described previously (11) , preceded by PCR using NAT1 specific primers [12] . Briefly, distinction between the NAT1*3, *4, *10 and *11 alleles was carried out by hybridization at 42°C overnight of allele specific oligonucleotides to PCR products spotted on a membrane. The NAT1*3, *4, *10 and *11 alleles were detected by hybridizing an antisense oligonucleotide for each allele to a separate membrane: NAT1*3 (5 0 c 32 P-ATP-agg cca tct tta aaa tac att tat tat ta), NAT1*4 (5 0 c 32 P-ATP-gcc atc ttt aaa aga cat tta tta tta tt), NAT1*10 (5 0 c 32 P-ggc cat ctt taa aat aca ttt ttt att at) and NAT1*11 (5 0 c 32 P-aaa ata cat tta tta tta tta tta ttt gaa aag g). Non-specific binding was removed by 30 min washing in 2· SSC, 0.1% SDS at 60°C for NAT1*4, NAT*10, NAT*11 and at 59°C for NAT1*3. In each experiment three blood samples of known genotype were used as controls for PCR as well as for hybridization. Their sequence was confirmed by DNA sequencing.
For genotype determination four X-ray films were read at the same time. The samples were classified in duplicate as NAT1*3, NAT1*4, NAT1*10 or NAT1*11 homozygote or heterozygote, by two independent observers.
NAT2 polymorphisms at positions 341, 590, 803 and 857 were detected by restriction fragment length polymorphism (RFLP) as described earlier [13] . In each experiment three known blood samples were used as controls for PCR as well as for RFLP analyses and the sequence was confirmed by DNA sequencing. The alleles were determined according to the known nomenclature [14] . G 191 A is not determined because it is not seen in Caucasian people [1] and we did not determine the silent mutations at nt 282 and 481.
Presence or absence of the GSTM1 and GSTT1 gene was determined by multiplex PCR as described by Chen et al. [15] . Briefly, segments of GSTM1 and GSTT1 were amplified along with a segment of human b-globin. The PCR products were analyzed on 2% agarose gels. A fragment of 215 bp indicated the presence of GSTM1, a fragment of 480 bp indicated the presence of GSTT1 and a fragment of 268 bp indicated the positive internal control b-globin. All laboratory analyses were performed blinded for case or control status and two observers independently classified all sample results.
Smoking
Smoking status was assessed at baseline by self-administered questionnaire. In this analysis three smoking classes were considered. Women, who reported smoking in the past, were classified as former smokers. Women who smoked at baseline were classified as current smokers and women who have never smoked were classified as never smokers. For women who smoked currently, information on dose was available and categorized as <10, 10-19, P20 cigarettes/day.
Data analysis
For ten women the smoking status was not known. DNA was insufficient or the genotyping method failed for NAT1 in 368 participants (19% cases and 19% subcohort), for NAT2 in 260 women (10% cases and 12% subcohort), and GSTM1 or GSTT1 genotyping was not possible in 458 women (24% cases and 22% subcohort). The percentage successful genotyping is slightly higher for NAT1 and NAT2 than for the GSTM1 and GSTT1. GSTM1 and GSTT1 were determined by a multiplex PCR. An internal control is necessary as control for the PCR success in case of a null genotype, which results in two sets of primers instead of one. This could influence the percentage visible PCR product. Furthermore, we did a pilot study for evaluating such a multiplex PCR and decided that it was more efficient to perform one multiplex PCR with three primers than two multiplex PCR with two primer sets.
For NAT1 the corresponding phenotype is not clear. An initial report on increased activity associated with the NAT1*10 allele [16] could not be supported in subsequent studies [17] [18] [19] [20] . However, we maintain the distinction of NAT1*10 and non NAT1*10 in our studies. Women with at least one NAT1*10 allele were classified as rapid acetylators and the rest as slow acetylators. Rapid acetylators served as the reference group in all analyses.
For NAT2 genotype carriers of a NAT2*4 or NAT2*12 allele were classified as rapid and the rest as slow acetylators [14] . Rapid acetylators were used as reference group. According to some data individuals homozygous for NAT2*5 alleles are the slowest acetylators [21] , and therefore we also analyzed these individuals compared to the rapid acetylators.
Homozygous GSTM1 null carriers were compared to the reference group of women with at least one GSTM1 present, analogous to GSTT1.
Since the 1000 women constitute a random sample of the total cohort (n = 25,769), the case cohort analysis was adopted. Multiplication of the person years in the reference group by 25.8 (the inverse of the subcohort non-cases sampling fraction) enabled us to analyze the case cohort as a full cohort, in which person years are unbiased estimates of true person years. Incidence rate ratios (IRR) and corresponding 95% CIs for breast cancer were estimated using Poisson regression models. Robust 95% CIs were calculated to account for additional variance introduced by sampling for the cohort [22] .
We included women for whom the genotyping was successful, for NAT1 genotyping this resulted in 764 cases and 810 controls, for NAT2 genotyping this were 845 cases and 875 controls, and for GSTM1 and GSTT1 this resulted in 717 cases and 767 controls. For 676 cases and 669 controls all genotyping was successful. We first analyzed the main effects of smoking and of the different genotypes separately. The joint effect of each at risk genotype and smoking was analyzed by combining genotype and smoking status. p Values for tests for trend were calculated.
We also evaluated the effect of a combination of several putative at risk genotypes. According to the number of putative at risk genotypes they possess, women were categorized in five subgroups: none (reference group), women with only one putative at risk genotype (defined as 'non NAT1*10' or 'NAT2 slow genotype' or 'GSTM1 null genotype or 'GSTT1 null genotype'), two, three and four putative at risk genotypes.
Factors considered for confounding were age, DOM cohort (1, 3, 4) , body mass index (BMI) (continuous), nulliparity (yes/no), age at first full term pregnancy (not applicable, <24, 24-27, P28), menopause (yes/no), menopausal age (continuous), family history of breast cancer (yes/no). We decided to include possible confounders in the model if exclusion changed the estimate by more than 10%. Since this was the case for age and DOM cohort, the final models contain the determinants of interest (smoking, genotype or a combination) and the variables age and DOM cohort. Analyses were performed using SPSS 9.0 and Stata 6.0.
Results
General characteristics, allele frequencies for NAT1 and NAT2 and genotype frequencies for GSTM1 and GSTT1 of the breast cancer cases and the cohort sample are presented in Table 1 . No significant difference was observed between the genotyped and non-genotyped persons with respect to these characteristics (data not shown). Breast cancer in first degree relatives was more frequent in cases than in the cohort sample. The distribution of NAT1, NAT2 (and very slow NAT2*5) and GSTM1 genotypes was similar among cases and the cohort sample and revealed no increased breast cancer risk. From the cases, 38% and from the cohort sample 29% had the GSTT1 null genotype.
Women with GSTT1 null genotype showed a statistically significant, increased breast cancer risk (RR = 1.30 (95% CI 1.04-1.64)), compared to women with GSTT1 present (Table 2 ). When we analyzed the effects of each genotype separately in the subsample of cases and controls for which we had complete genotype information (676 cases; 669 controls), results were largely the same. (38) 225 (29) Values are mean (SD) and numbers (percentage). Compared to women who never smoked, women smoking a high dose of cigarettes (20 or more per day) showed a modest increase in breast cancer risk, although not statistically significant (RR = 1.28 (95% CI 0.83-1.96)) ( Table 3) . No joint effect of smoking and genotype was observed for NAT1, NAT2 nor GSTM1 genotype (Table 4) , nor for smoking in combination with the very slow NAT2*5 (data not shown). Compared to women who never smoked with GSTT1, women without GSTT1 (null genotype) who smoked in the past had an increased breast cancer risk, RR = 2.55 (95%CI 1.10-5.90). However, for current smokers no increased risk was observed (Table 5) .
When women were classified according to their cumulative number of putative at risk genotypes (non NAT1*10 or NAT2 slow genotype, GSTM1 or GSTT1 null genotype), none, one, two, three or four, an increased breast cancer risk with increasing number of putative at risk genotype was apparent. The effect showed a doseresponse relation (p for trend 0.01). The risk was more than doubled in women with all four risk genotypes, RR = 2.45 (95% CI 1.24-4.86) ( Table 6 ). Numbers were too small to determine interaction with smoking.
Results did not change, when analyzing pre-and postmenopausal women separately.
Discussion
The present study shows that women with increasing number of putative at risk genotypes showed increased breast cancer risk in a dose dependent manner. An effect of GSTT1 null genotype on breast cancer risk was also observed, especially for women who have smoked in the past.
A major advantage of case cohort approach over a nested case control study is that it is analyzed as a full cohort and breast cancer incidence rates can be estimated. The incidence rate observed in the first DOM cohort (50 to 70 years in 1975, follow-up to 1996), IR = 2.64/1000 person years, is of the same order of magnitude as the incidence rate for The Netherlands for 60 to 64 years old women in 1990, IR = 2.52/1000 person years in 1990 [23] . This implies that follow-up of the cohort for breast cancer is virtually complete.
Moreover, in this study smoking data were collected prior to disease occurrence, thus excluding recall bias. Further exclusion of cases occurring in the first year of follow-up did not change the results, indicating that reporting of smoking habits was not biased by presence of latent disease. Genotyping was done blinded to case or control status and misclassification is therefore random and will, if anything, dilute results.
We did not observe increased breast cancer risk for different NAT1, NAT2 and GSTM1 genotypes separately. However, a significant 30% increased breast cancer risk was observed for GSTT1 null genotype (RR = 1.30 (95% CI 1.04-1.64), especially among former smokers (RR = 2.55 (95% CI 1. 10-5.90 ). An effect of GSTT1 null genotype on breast cancer risk is in agreement with three previous studies [24] [25] [26] but such risk was not observed in eight other studies [27] [28] [29] [30] [31] [32] [33] [34] . Our observation may be a chance finding, also in view of the absence of an association for current smokers, even for those who smoke more than 20 cigarettes per day. Another explanation might be that former smokers reflect more accurately exposure to carcinogens and the necessary subsequent latency time. Duration may thus be important, but unfortunately this was not asked in the questionnaire. Also, information on exposure to environmental tobacco smoke is lacking.
Our result that NAT2 did not modify smoking effect is in accordance with five other studies [5, 8, [35] [36] [37] . In contrast, three studies showed an interaction [38] [39] [40] , and it was found that DNA-adduct level were significantly elevated in the mammary DNA from women with slow NAT2 acetylator genotype [41, 42] . We therefore analyzed the very slow NAT2 acetylators (NAT2*5) separately. This revealed no increased breast cancer risk, neither by itself, nor in combination with smoking status. Inconsistencies in results in studies may partly be explained by differences in NAT2 polymorphism determinations, which may lead to misclassification of acetylator type imputed from the genotype [1] .
We observed an increased breast cancer risk for women with increasing number of putative at risk genotypes, which was in a dose-response manner. Two other studies reported a positive association of two putative at risk genotypes (GSTM1 and GSTT1 null genotype) and breast cancer [24, 25] and one study reported that genetic polymorphisms of NAT1 and NAT2 modulated breast cancer risk in the presence of GSTM1 and GSTT1 [43] . This may indicate that other enzymes compensate detoxification or activation of carcinogens in case of a single putative at risk genotype.
In conclusion, the results of this study suggest that presence of three or more metabolic putative at risk genotypes increase breast cancer risk in women, but none of these genotypes alone modified the effect of smoking on breast cancer.
